{"paper_id":"9d370338-cb18-4a97-8bdf-85157101cf69","body_text":"The clinical management of chronic lymphocytic leukemia (CLL) patients with fludarabine-resistant disease or tumor cells with 17p deletions remains problematic.1 High-dose glucocorticoids (HDGCs) are among the most effective treatment approaches for such patients, as well as elderly patients who cannot tolerate conventional chemotherapy. However, HDGCs are not without significant side effects and are only palliative in nature.2 Identification of nontoxic agents that could improve the therapeutic efficacy of HDGCs would help significantly in managing these patients.\nWe then examined the effects of Danazol specifically on CLL cells with 17p deletions (Figure 2c, bottom left panel). At a dose of 10 μM, Danazol remained capable of killing such cells, especially in combination with Dex. Compared with CLL cells without this cytotogenetic abnormality, 17p− tumor cells appeared less sensitive to Danazol, with or without Dex, although the differences were not statistically significant (Figure 2c, right panel). Note the results for Figure 2c were obtained with cryopreserved cells and the higher levels of spontaneous death following thawing account for the lower specific death levels in comparison with Figure 2b, which were obtained with fresh tumor cells.\nThis is a preview of subscription content, access via your institution\nRelevant articles\nOpen Access articles citing this article.\n-\nDanazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia\nAnnals of Hematology Open Access 22 December 2015\nAccess options\nSubscribe to this journal\nReceive 12 print issues and online access\n251,40 € per year\nonly 20,95 € per issue\nBuy this article\n- Purchase on SpringerLink\n- Instant access to the full article PDF.\n39,95 €\nPrices may be subject to local taxes which are calculated during checkout\nReferences\nGribben JG, O'Brien S . Update on therapy of CLL. J Clin Oncol 2011; 29: 544–550.\nCastro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L et al. Rituximab in combination with high-dose methylprednisolone for the treatment of CLL. Leukemia 2009; 23: 1779–1789.\nFontana V, Dudkiewicz P, Ahn ER, Horstman L, Ahn YS . Danazol therapy combined with intermittent application of chemotherapy induces lasting remission in myeloproliferative disorder (MPD). Hematology 2011; 16: 90–94.\nCicardi M, Zingale LC, Pappalardo E, Folcioni A, Agostoni A . Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003; 82: 274–281.\nMorcavallo PS, Leonida A, Rossi G, Mingardi M, Martini M, Monguzzi R et al. Hereditary angioedema in oral surgery. J Oral Maxillofac Surg 2010; 68: 2307–2311.\nJohanssen S, Allolio B . Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007; 157: 561–569.\nSpaner DE . Oral high-dose glucocorticoids and ofatumumab in flurarabine-resistant chronic lymphocytic leukemia. Leukemia 2011; e-pub ahead of print 8 November 2011; doi:10.1038/leu.2011.329.\nBoruchov DM, Gururangan S, Driscoll MC, Bussel JB . Multiagent induction and maintenance therapy for patients with refractory ITP. Blood 2007; 110: 3526–3531.\nShepherd J . Danazol and plasma lipoprotein metabolism. Int J Gynaecol Obstet 1995; 50 (Suppl 1): S23–S26.\nAlvarez G, Gómez-Galicia D, Rodríguez-Fragoso L, Marina V, Dorantes L, Sánchez-Alemán M et al. Danazol improves thrombocytopenia in HCV patients treated with peginterferon and ribavirin. Ann Hepatol 2011; 10: 458–468.\nMatalliotakis I, Neonaki M, Koumantaki Y, Goumenou A, Kyriakou D, Koumantakis E . A randomized comparison of danazol and leuprolide acetate suppression of serum-soluble CD23 levels in endometriosis. Obstet Gynecol 2000; 95: 810–813.\nTomic J, Lichty B, Spaner DE . Aberrant interferon-signaling is associated with aggressive CLL. Blood 2011; 117: 2668–2680.\nTanaka T . Danazol regulates the functions of normal human endometrial stromal cell subpopulations by modifying endometrial cytokine networks. Int J Mol Med 2009; 23: 421–428.\nHorstman L, Jy W, Arce M, Ahn YS . Danazol distribution in plasma and cell membranes as related to altered cell properties: implications for mechanism. Am J Hematol 1995; 50: 179–187.\nAcknowledgements\nThis study was supported by the Canadian Institutes of Health Research (CIHR) and the Leukemia and Lymphoma Society of Canada (to DS) and a QEII-SST graduate scholarship from the University of Toronto (to ST).\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nCompeting interests\nThe authors declare no conflict of interest.\nRights and permissions\nAbout this article\nCite this article\nTung, S., Spaner, D. A role for Danazol in chronic lymphocytic leukemia. Leukemia 26, 1684–1686 (2012). https://doi.org/10.1038/leu.2011.386\nPublished:\nIssue date:\nDOI: https://doi.org/10.1038/leu.2011.386","source_license":"CC0","license_restricted":false}